share_log

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

Benzinga ·  Nov 2 03:00

6 analysts have shared their evaluations of Alnylam Pharmaceuticals (NASDAQ:AGIO) during the recent three months, expressing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings05100
Last 30D02000
1M Ago02000
2M Ago01100
3M Ago00000

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.5, with a high estimate of $56.00 and a low estimate of $51.00. This current average represents a 3.17% decrease from the previous average price target of $55.25.

bigjpg

Decoding Analyst Ratings: A Detailed Look

A clear picture of Alnylam Pharmaceuticals...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment